Table 1 Baseline patient characteristics.
Four-drug group (n = 22) | Three-drug group (n = 108) | ||
|---|---|---|---|
Age (years), median [IQR] | 51 [45–55] | 55 [44–61] | |
Sex, n (%) | Female | 22 (100) | 108 (100) |
Male | 0 (0) | 0 (0) | |
Height (cm), median [IQR] | 157.0 [155.0–163.4] | 156.3 [153.0–160.2] | |
Weight (kg), median [IQR] | 56.3 [52.2–63.2] | 56.4 [50.5–63.2] | |
Body surface area (m2), median [IQR] | 1.59 [1.52–1.69] | 1.56 [1.49–1.64] | |
BMI (kg/m2), median [IQR] | 22.1 [20.6–25.3] | 23.3 [20.5–26.9] | |
ECOG PS, n (%) | 0 | 22 (100) | 103 (95.4) |
1 | 0 (0) | 5 (4.6) | |
Stage, n (%) | I | 5 (22.7) | 10 (9.3) |
II | 12 (54.5) | 62 (57.4) | |
III | 5 (22.7) | 30 (27.8) | |
IV | 0 (0) | 4 (3.7) | |
Recurrence | 0 (0) | 2 (1.9) | |
History of smoking habit, n (%) | Yes | 5 (22.7) | 30 (27.8) |
No | 17 (77.3) | 78 (72.2) | |
History of alcohol habit, n (%) | Yes | 7 (31.8) | 39 (36.1) |
No | 15 (68.2) | 69 (63.9) | |
Anthracycline, n (%) | AC | 22 (100) | 53 (49.1) |
EC | 0 (0) | 5 (4.6) | |
FEC | 0 (0) | 50 (46.3) | |
